Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
By J. Berlin, P. Catalano, James P. Thomas, J. Kugler, D. Haller, A. Benson. Journal of Clinical Oncology, 2002
761 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/9a802e00a3fca95635b8e5b9c10556e88be7a064
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, background): “Negative phase III results despite promising single-arm phase II data are, unfortunately, a common outcome in pancreatic cancer trials.(3-10) These collective data suggest that in this disease, a single-arm, phase II trial design may not be not optimal.”
- Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021, background): “significant survival advantage was observed for patients receiving the combination regimen.(145) Recent randomized trials from Asia show that gem-”